Evidence map›Paper›PMID 34503097›Full record

ReviewCancers2021

Breast Cancer-Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies-An Updated Review.

Sergiusz Łukasiewicz, Marcin Czeczelewski, Alicja Forma, Jacek Baj, Robert Sitarz, Andrzej Stanisławek

3 registry-linked trialsOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 978 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
978citing papers in PubMed, 10 pooled it
90.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05680311 nacompletednot on this map

Is Autotaxin a Promising Biomarker for Breast Cancer

TypeinterventionalSponsorAnkara Etlik City HospitalRan2019 to 2021Enrolled110ConditionsBreast CancerArmsmeasurement of serum autotaxin serum level
NCT05850637 phase2completednot on this map

Phase II Study to Evaluate the Effectiveness and Toxicity of Adjuvant Ultra-hypofractionated Radiotherapy for the Treatment of Early and Locally Advanced Breast Cancer

TypeinterventionalSponsorPrevent Senior InstituteRan2019 to 2023Enrolled60ConditionsBreast Cancer FemaleArmsadjuvant ultra-hypofractionated radiotherapy
NCT07763080 narecruitingnot on this mapstarted 2026, after this paper: background citation

Reverse Fly Exercise On Supraspinatus Tendinitis In Patients Receiving Aromatase Inhibitors Therapy After Mastectomy

TypeinterventionalSponsorCairo UniversityRan2026 to 2027Enrolled40ConditionsMastectomy, Aromatase Inhibitors TherapyArmsReverse fly excercise, Control group
3 · Its place in the literature

Who cites it

978 citing papers in PubMed, 10 syntheses or guidelines pooled it, 1,723 citations in OpenAlex.

  1. Mastitis as a risk factor for breast cancer: a systematic review and meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Trial
  12. Article
  13. Article
  14. Utilization ofAdvances in radiation oncology · 2026
    Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article

918 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Sergiusz ŁukasiewiczDepartment of Surgical Oncology, Center of Oncology of the Lublin Region St. Jana z Dukli, 20-091 Lublin, Poland.ORCID 0000-0002-8033-8196
Marcin CzeczelewskiDepartment of Forensic Medicine, Medical University of Lublin, 20-090 Lublin, Poland.
Alicja FormaDepartment of Forensic Medicine, Medical University of Lublin, 20-090 Lublin, Poland.ORCID 0000-0001-8714-7627
Jacek BajDepartment of Human Anatomy, Medical University of Lublin, 20-090 Lublin, Poland.ORCID 0000-0002-1372-8987
Robert SitarzDepartment of Surgical Oncology, Center of Oncology of the Lublin Region St. Jana z Dukli, 20-091 Lublin, Poland.
Andrzej StanisławekDepartment of Surgical Oncology, Center of Oncology of the Lublin Region St. Jana z Dukli, 20-091 Lublin, Poland.
Medical University of Lublin · PLLublin Oncology Center · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer (BC) is the most frequently diagnosed cancer in women worldwide with more than 2 million new cases in 2020. Its incidence and death rates have increased over the last three decades due to the change in risk factor profiles, better cancer registration, and cancer detection. The number of risk factors of BC is significant and includes both the modifiable factors and non-modifiable factors. Currently, about 80% of patients with BC are individuals aged >50. Survival depends on both stage and molecular subtype. Invasive BCs comprise wide spectrum tumors that show a variation concerning their clinical presentation, behavior, and morphology. Based on mRNA gene expression levels, BC can be divided into molecular subtypes (Luminal A, Luminal B, HER2-enriched, and basal-like). The molecular subtypes provide insights into new treatment strategies and patient stratifications that impact the management of BC patients. The eighth edition of TNM classification outlines a new staging system for BC that, in addition to anatomical features, acknowledges biological factors. Treatment of breast cancer is complex and involves a combination of different modalities including surgery, radiotherapy, chemotherapy, hormonal therapy, or biological therapies delivered in diverse sequences.

Indexed as

breast cancerclassificationdiagnosisepidemiologymarkerprognosisrisk factorstreatment

Identifiers

PMID34503097
PMCPMC8428369
OpenAlexW3193347331

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.